AstraZeneca and Bristol Myers Squibb Eye $400 Billion Merger
AstraZeneca Plc and Bristol Myers Squibb engaged in initial talks regarding a potential merger that could result in the formation of one of the largest pharmaceutical entities globally, boasting a combined valuation of nearly $400 billion, as reported by an individual knowledgeable about the matter. A potential deal would carry regulatory risk due to concerns regarding its assessment by US antitrust authorities under President Donald Trump’s administration, the individual stated on condition of anonymity. Trump has been concentrating on domestic investments in the sector and enhancing US manufacturing. Last year, AstraZeneca announced intentions for a direct listing in the US, seeking to leverage the more favourable valuations present in the American market. This move would signify that a UK-based entity is essentially acquiring a significant player in the US pharmaceutical sector. AstraZeneca’s share price has more than quadrupled during Pascal Soriot’s 14-year tenure as CEO, significantly outperforming the broader FTSE 100 index and its primary British competitor, GSK. Second-quarter results last week indicated that robust demand for cancer and rare-disease medications persists as a key driver of AstraZeneca’s growth.
Cancer treatments represented approximately $25 billion in sales for 2025, constituting nearly half of the total market. In comparison, treatments for cardiovascular, renal, and metabolism conditions generated around $12 billion. Oncology drugs represented over 40% of Bristol Myers’ total sales during the initial half of 2026, with the cancer immunotherapies from both companies being in direct competition. “I would expect a Trump FTC to scrutinize the merger, and if there are significant overlaps in certain drugs and late-stage pipeline overlaps, it would require meaningful divestitures,” said Andre Barlow, referring to the US Federal Trade Commission. Bristol Myers has been engaging in smaller transactions to acquire new pharmaceuticals as it confronts diminishing revenues from its older products, several of which are on the verge of facing generic competition. In 2019, Bristol Myers acquired Celgene for approximately $80 billion, securing its leading blood cancer treatment, Revlimid, which subsequently emerged as Bristol’s highest-grossing product.
Revlimid has already lost patent protection, and its current leading products – cancer immunotherapy Opdivo and blood thinner Eliquis – are at risk of losing patent protection by 2028. Barlow observed that in the agreement concerning Celgene, the Trump FTC mandated the divestiture of the psoriasis treatment Otezla, a significant transaction valued at $13.4 billion. “There is bipartisan support to scrutinize pharma deals, so I would imagine that even the Trump FTC would ask the broader questions relating to bundling of products and a lack of future innovation, in addition to scrutinizing all direct overlaps,” he said. Bristol Myers elevated its full-year revenue and profit projections last week, driven by robust sales of Eliquis and newer pharmaceuticals that propelled second-quarter results significantly beyond analysts’ expectations.
Its promising newer drugs and pipeline assets include an experimental blood thinner, milvexian; anaemia treatment, Reblozyl; and heart drug, Camzyos. Consideration of the potential deal arises approximately twelve years following AstraZeneca’s successful defence against a takeover bid from its larger US competitor, Pfizer. Large pharmaceutical transactions have become infrequent in recent years, partly due to apprehensions regarding antitrust issues and pressure from the US to maintain low drug prices. In addition to the Bristol Myers and Celgene transaction, AbbVie acquired Allergan in 2020, while Takeda and Shire merged in 2019.
